Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L, Oberlick E, Liu T, McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E, Nagaraju GP, Havel L, Marcus A, Nahta R, O'Regan R. Taliaferro-Smith L, et al. Among authors: havel l. Oncotarget. 2015 Mar 10;6(7):4757-72. doi: 10.18632/oncotarget.3023. Oncotarget. 2015. PMID: 25749031 Free PMC article.
Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion.
Richardson AM, Havel LS, Koyen AE, Konen JM, Shupe J, Wiles WG 4th, Martin WD, Grossniklaus HE, Sica G, Gilbert-Ross M, Marcus AI. Richardson AM, et al. Clin Cancer Res. 2018 Jan 15;24(2):420-432. doi: 10.1158/1078-0432.CCR-17-1776. Epub 2017 Dec 5. Clin Cancer Res. 2018. PMID: 29208669 Free PMC article.
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, de Castro G Jr, Havel L, Bernabé Caro R, Losonczy G, Lee JS, Kowalski DM, Andric Z, Califano R, Veatch A, Gerstner G, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV. Reck M, et al. Among authors: havel l. Lung Cancer. 2024 Oct;196:107924. doi: 10.1016/j.lungcan.2024.107924. Epub 2024 Aug 10. Lung Cancer. 2024. PMID: 39306923 Clinical Trial.
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Goksu SS, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators. Cheng Y, et al. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. N Engl J Med. 2024. PMID: 39268857 Clinical Trial.
Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data.
Krakorova G, Domecky P, Blazek J, Pesek M, Venclicek O, Havel L, Hrnciarik M, Krejci J, Mullerova A, Marel M, Duba J, Svaton M. Krakorova G, et al. Among authors: havel l. Transl Lung Cancer Res. 2024 Jul 30;13(7):1495-1504. doi: 10.21037/tlcr-24-108. Epub 2024 Jul 15. Transl Lung Cancer Res. 2024. PMID: 39118875 Free PMC article.
90 results